Skip to main content
. 2020 Jun 9;10:9330. doi: 10.1038/s41598-020-66458-z

Figure 8.

Figure 8

Saroglitazar treatment reduces lipotoxic compounds in the liver. Endogenous metabolic profiles of liver samples taken from mice fed with CDNW or WDSW treated with/without saroglitazar were determined using ultra high performance liquid chromatography- mass spectrometry (UHPLC-MS). Box plots of (A) ceramide, (B) sphingomyelin, (C) phosphatidylcholine, (D) phosphatidylethanolamine. Data are expressed as the mean ± SEM for 6–12 mice per group. #p < 0.05, ##p < 0.001 compared to CDNW; *p < 0.05, **p < 0.001 compared to WDSW, vehicle control.